Jose Sollano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jose Sollano has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Ari Fahrial Syam
Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital
4 shared publications - Andrew Ming-Liang Ong
Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore
3 shared publications - Duc Trong Quach
Department of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam
3 shared publications - Phuripong Kijdamrongthum
Division of Gastroenterology, Department of Internal Medicine Chiang Mai University Chiang Mai Thailand
3 shared publications - Rahela Ambaras Khan
Hospital Kuala Lumpur
3 shared publications - Sakkarin Chirapongsathorn
Division of Gastroenterology and Hepatology, Department of Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand
3 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70274
Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.
- 2 June 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70274
Open AccessProton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.
- Open Access
- 26 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (6) , 1685-1700
Rationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.
- 26 March 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (6) , 1685-1700
Open AccessRationalizing Proton Pump Inhibitor Use: Southeast Asia Consensus Recommendations
Background and Aim: Proton pump inhibitors (PPIs) are integral to managing many gastrointestinal conditions. However, the prevalent inappropriate PPI prescription across Southeast Asia (SEA) is concerning. Given the absence of locally tailored recommendations to inform clinical practice, this consensus document aims to provide recommendations for PPI rationalization to healthcare providers in the region. Methods: The SEA PPI Rationalization Working Group is steered by 14 experts practicing across Malaysia, Thailand, Singapore, Vietnam, the Philippines, and Indonesia. The experts convened to review existing evidence and develop recommendations and to conduct an anonymous voting as per the modified Delphi method. Results: Twenty statements were formulated, focusing on areas of (i) extent and impact of PPI overprescription (four statements), (ii) benefits and barriers to PPI rationalization (two statements), (iii) START/STOPP criteria for PPI (nine statements), and (iv) PPI rationalization strategies (five statements). The consensus document underscores the widespread inappropriate long‐term PPI prescription across SEA, which may have adverse clinical outcomes. Although rationalizing PPI use may be beneficial, the experts acknowledge the challenges of implementing PPI rationalization. The experts also outlined specific indications to guide PPI initiation and advised regular review to rationalize a PPI when no longer indicated. This is followed by PPI rationalization strategies, including shared decision‐making, prescribing alginate as a rescue therapy in gastroesophageal reflux disease, and further evaluation for reinitiation of PPI when clinically warranted. Conclusions: This consensus document serves to improve PPI prescribing and deprescribing practices in SEA and to provide recommendations on rationalization strategies.
- Open Access
Proton Pump Inhibitors Prescribing Behaviors and Rationalisation Strategies among Healthcare Providers in the Southeast Asia
SUMMARY: Background: Despite its widespread use, real-world evidence on proton pump inhibitor (PPI) prescribing and rationalisation practices in Southeast Asia (SEA) remains limited. This study aimed to investigate current prescribing behaviors and rationalisation strategies among SEA healthcare professionals. Methods: The SEA PPI Rationalisation Working Group designed and disseminated an online survey across SEA via professional networks. The questionnaire included sections on demographics, PPI prescribing habits, and rationalisation strategies. Reliability testing of the questionnaire yielded a Cronbach’s alpha of 0.799. Content validity was confirmed by a panel of 10 gastroenterology experts, with perfect agreement on relevance and clarity (I-CVI, kappa, SCVI/Ave = 1.0). K-mode clustering was used to explore prescribing patterns. The main outcome was the identification of prescribing patterns and rationalisation strategies for long-term PPI use. Findings: Among the 869 responses received, 763 valid entries were analysed (response rate: 87.8%), with 49% of the respondents being gastroenterologists. PPIs were most prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%). Long-term PPI use was reported by 48.9% of the participants, while 59.2% reported reassessing indications at every follow-up visit. Rationalisation strategies included dose tapering (46.8%), on-demand use (45.9%), and step-down to antacids or alginates (44.8%). Cluster analysis identified two profiles: proactive prescribers (n=326, 42.7%) who followed clinical guidelines, applied individualised dosing, and routinely reassessed therapy, and conservative prescribers (n=437, 57.3%) who used PPIs more restrictively and rationalised less frequently. Interpretation: Marked variability in PPI prescribing and rationalisation across SEA highlights the need for regional consensus to support evidence-based practice. Funding: This study was supported by Reckitt Benckiser (Singapore) Pte Ltd ., which provided funding for article processing charge Evidence before this study: Although proton pump inhibitors (PPIs) are widely prescribed across Southeast Asia (SEA), there is limited real-world evidence examining the prescribing behaviors and rationalisation practices within the region. Previous research predominantly focused on Western countries and raised concerns regarding the over-prescription and prolonged use of PPIs. However, no studies have comprehensively addressed the regional variability in PPI prescribing or the strategies employed to rationalise their use in SEA. Added value of this study: This study provides the first region-wide analysis of PPI prescribing practices and rationalisation strategies in SEA. By employing cluster analysis, the study identifies two distinct prescriber profiles: proactive prescribers, who follow clinical guidelines and individualise treatment, and conservative prescribers, who use PPIs more restrictively and apply rationalisation strategies less frequently. The study offers critical insights into the current prescribing landscape in SEA, highlighting the need for evidence-based regional guidelines to optimise PPI use. Implications of all the available evidence: The findings suggest that significant variability in PPI prescribing exists across SEA, underscoring the necessity for region-specific guidelines. Policymakers should use these insights to inform evidence-based clinical guidelines for PPI use and rationalisation. Additionally, future research should explore the effectiveness of rationalisation strategies and identify barriers to their implementation within diverse healthcare systems in SEA.
Open AccessProton Pump Inhibitors Prescribing Behaviors and Rationalisation Strategies among Healthcare Providers in the Southeast Asia
SUMMARY: Background: Despite its widespread use, real-world evidence on proton pump inhibitor (PPI) prescribing and rationalisation practices in Southeast Asia (SEA) remains limited. This study aimed to investigate current prescribing behaviors and rationalisation strategies among SEA healthcare professionals. Methods: The SEA PPI Rationalisation Working Group designed and disseminated an online survey across SEA via professional networks. The questionnaire included sections on demographics, PPI prescribing habits, and rationalisation strategies. Reliability testing of the questionnaire yielded a Cronbach’s alpha of 0.799. Content validity was confirmed by a panel of 10 gastroenterology experts, with perfect agreement on relevance and clarity (I-CVI, kappa, SCVI/Ave = 1.0). K-mode clustering was used to explore prescribing patterns. The main outcome was the identification of prescribing patterns and rationalisation strategies for long-term PPI use. Findings: Among the 869 responses received, 763 valid entries were analysed (response rate: 87.8%), with 49% of the respondents being gastroenterologists. PPIs were most prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%). Long-term PPI use was reported by 48.9% of the participants, while 59.2% reported reassessing indications at every follow-up visit. Rationalisation strategies included dose tapering (46.8%), on-demand use (45.9%), and step-down to antacids or alginates (44.8%). Cluster analysis identified two profiles: proactive prescribers (n=326, 42.7%) who followed clinical guidelines, applied individualised dosing, and routinely reassessed therapy, and conservative prescribers (n=437, 57.3%) who used PPIs more restrictively and rationalised less frequently. Interpretation: Marked variability in PPI prescribing and rationalisation across SEA highlights the need for regional consensus to support evidence-based practice. Funding: This study was supported by Reckitt Benckiser (Singapore) Pte Ltd ., which provided funding for article processing charge Evidence before this study: Although proton pump inhibitors (PPIs) are widely prescribed across Southeast Asia (SEA), there is limited real-world evidence examining the prescribing behaviors and rationalisation practices within the region. Previous research predominantly focused on Western countries and raised concerns regarding the over-prescription and prolonged use of PPIs. However, no studies have comprehensively addressed the regional variability in PPI prescribing or the strategies employed to rationalise their use in SEA. Added value of this study: This study provides the first region-wide analysis of PPI prescribing practices and rationalisation strategies in SEA. By employing cluster analysis, the study identifies two distinct prescriber profiles: proactive prescribers, who follow clinical guidelines and individualise treatment, and conservative prescribers, who use PPIs more restrictively and apply rationalisation strategies less frequently. The study offers critical insights into the current prescribing landscape in SEA, highlighting the need for evidence-based regional guidelines to optimise PPI use. Implications of all the available evidence: The findings suggest that significant variability in PPI prescribing exists across SEA, underscoring the necessity for region-specific guidelines. Policymakers should use these insights to inform evidence-based clinical guidelines for PPI use and rationalisation. Additionally, future research should explore the effectiveness of rationalisation strategies and identify barriers to their implementation within diverse healthcare systems in SEA.
- Open Access
- 30 April 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (2) , 117-128
Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.
- 30 April 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (2) , 117-128
Open AccessRole of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey
Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.
- Open Access
- 30 January 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (1) , 37-55
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.
- 30 January 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (1) , 37-55
Open AccessOptimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
The lack of clear definition and classification for “moderate ulcerative colitis (UC)” creates ambiguity regarding the suitability of step-up versus top-down treatment approaches. In this paper, experts address crucial gaps in assessing and managing moderate UC. The Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition comprised 24 experts who convened to share, discuss and vote electronically on management recommendations for moderate UC. Experts emphasized that the goal of treating UC is to attain clinical, biomarker, and endoscopic remission using cost-effective strategies such as 5-aminosalicylates (5-ASAs), well-tolerated therapy that can be optimized to improve outcomes. Experts agreed that 5-ASA therapy could be optimized by maximizing dosage (4 g/day for induction of remission), combining oral and topical administration, extending treatment duration beyond 8 weeks, and enhancing patient adherence through personalized counselling and reduced pill burden. Treatment escalation should ideally be reserved for patients with predictors of aggressive disease or those who do not respond to 5-ASA optimization. Premature treatment escalation to advanced therapies (including biologics and oral small molecules) may have long-term health and financial consequences. This paper provides consensus-based expert recommendations and a treatment algorithm, based on current evidence and practices, to assist decision-making in real-world settings.
- Open Access
- 31 July 2023
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 21 (3) , 328-338
Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Background/Aims: Inflammatory bowel disease (IBD) is no longer a rare disease in Asia, thus it needs to prepare recommendations relevant to Asian patients. This study aimed to identify disparities in the process of the diagnosis of IBD in Asian countries/regions.Methods: In line with the 2020 Asian Organization for Crohn’s and Colitis annual meeting, a multinational web-based survey about Asian physicians’ perspectives on IBD was conducted. Results: A total of 384 Asian physicians (99 in China, 93 in Japan, 110 in Korea, and 82 in other Asian countries/regions) treating IBD patients from 24 countries/regions responded to the survey. Most respondents were gastroenterologists working in an academic teaching hospital. About half of them had more than 10 years of clinical experience in caring for patients with IBD. The European Crohn’s Colitis Organisation guideline was used most commonly for the diagnosis of IBD except for Japanese physicians who preferred their own national guideline. The Mayo score and Crohn’s Disease Activity Index were the most commonly used activity scoring systems for ulcerative colitis and Crohn’s disease, respectively. Endoscopy, not surprisingly, was the main investigation in assessing the extent and activity of IBD. On the other hand, there were disparities across countries/regions with regard to the favored modalities of small bowel and perianal evaluation of Crohn’s disease, as well as the use of serologic markers. Conclusions: Results of the present survey revealed practical behaviors of Asian physicians in the diagnosis of IBD. Investigating the reasons for different diagnostic approaches among countries/regions might help us develop Asian guidelines further.
- 31 July 2023
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 21 (3) , 328-338
Open AccessDiagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Background/Aims: Inflammatory bowel disease (IBD) is no longer a rare disease in Asia, thus it needs to prepare recommendations relevant to Asian patients. This study aimed to identify disparities in the process of the diagnosis of IBD in Asian countries/regions.Methods: In line with the 2020 Asian Organization for Crohn’s and Colitis annual meeting, a multinational web-based survey about Asian physicians’ perspectives on IBD was conducted. Results: A total of 384 Asian physicians (99 in China, 93 in Japan, 110 in Korea, and 82 in other Asian countries/regions) treating IBD patients from 24 countries/regions responded to the survey. Most respondents were gastroenterologists working in an academic teaching hospital. About half of them had more than 10 years of clinical experience in caring for patients with IBD. The European Crohn’s Colitis Organisation guideline was used most commonly for the diagnosis of IBD except for Japanese physicians who preferred their own national guideline. The Mayo score and Crohn’s Disease Activity Index were the most commonly used activity scoring systems for ulcerative colitis and Crohn’s disease, respectively. Endoscopy, not surprisingly, was the main investigation in assessing the extent and activity of IBD. On the other hand, there were disparities across countries/regions with regard to the favored modalities of small bowel and perianal evaluation of Crohn’s disease, as well as the use of serologic markers. Conclusions: Results of the present survey revealed practical behaviors of Asian physicians in the diagnosis of IBD. Investigating the reasons for different diagnostic approaches among countries/regions might help us develop Asian guidelines further.
- 5 January 2017
- Published by S. Karger AG in Digestion
- Vol. 95 (1) , 79-88
Asian Perspectives on Diagnostic and Therapeutic Strategies in Inflammatory Bowel Disease: Report and Analysis of a Survey with Questionnaires
Background: Diagnostic and therapeutic strategies in inflammatory bowel disease (IBD) vary among countries in terms of availability of modalities, affordability of health care resource, health care policy and cultural background. This may be the case in different countries in Eastern Asia. The aim of this study was to determine and understand the differences in diagnostic and therapeutic strategies of IBD between Japan and the rest of Asian countries (ROA). Methods: Questionnaires with regard to clinical practice in IBD were distributed to members of the International Gastroenterology Consensus Symposium Study Group. The responders were allowed to select multiple items for each question, as multiple modalities are frequently utilized in the diagnosis and the management of IBD. Dependency and independency of selected items for each question were evaluated by the Bayesian network analysis. Results: The selected diagnostic modalities were not very different between Japan and ROA, except for those related to small bowel investigations. Balloon-assisted enteroscopy and small bowel follow through are frequently used in Japan, while CT/MR enterography is popular in ROA. Therapeutic modalities for IBD depend on availability of such modalities in clinical practice. As far as modalities commonly available in both regions are concerned, there seemed to be similarity in the selection of each therapeutic modality. However, evaluation of dependency of separate therapeutic modalities by Bayesian network analysis disclosed some difference in therapeutic strategies between Japan and ROA. Conclusion: Although selected modalities showed some similarity, Bayesian network analysis elicited certain differences in the clinical approaches combining multiple modalities in various aspects of IBD between Japan and ROA.
- 5 January 2017
- Published by S. Karger AG in Digestion
- Vol. 95 (1) , 79-88
Asian Perspectives on Diagnostic and Therapeutic Strategies in Inflammatory Bowel Disease: Report and Analysis of a Survey with Questionnaires
Background: Diagnostic and therapeutic strategies in inflammatory bowel disease (IBD) vary among countries in terms of availability of modalities, affordability of health care resource, health care policy and cultural background. This may be the case in different countries in Eastern Asia. The aim of this study was to determine and understand the differences in diagnostic and therapeutic strategies of IBD between Japan and the rest of Asian countries (ROA). Methods: Questionnaires with regard to clinical practice in IBD were distributed to members of the International Gastroenterology Consensus Symposium Study Group. The responders were allowed to select multiple items for each question, as multiple modalities are frequently utilized in the diagnosis and the management of IBD. Dependency and independency of selected items for each question were evaluated by the Bayesian network analysis. Results: The selected diagnostic modalities were not very different between Japan and ROA, except for those related to small bowel investigations. Balloon-assisted enteroscopy and small bowel follow through are frequently used in Japan, while CT/MR enterography is popular in ROA. Therapeutic modalities for IBD depend on availability of such modalities in clinical practice. As far as modalities commonly available in both regions are concerned, there seemed to be similarity in the selection of each therapeutic modality. However, evaluation of dependency of separate therapeutic modalities by Bayesian network analysis disclosed some difference in therapeutic strategies between Japan and ROA. Conclusion: Although selected modalities showed some similarity, Bayesian network analysis elicited certain differences in the clinical approaches combining multiple modalities in various aspects of IBD between Japan and ROA.
- Open Access
- 28 April 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (5) , 945-952
Chronic hepatitis B virus in the Philippines
Multiple studies have shown a high prevalence of chronic hepatitis B (CHB) infection in the Philippines, not only in high‐risk populations but also in the general population. The most recent national study estimated HBsAg seroprevalence to be 16.7%, corresponding to an estimated 7.3 million CHB adults. The factors underlying the high prevalence of CHB and its sequelae include the inadequate use of vaccination for prevention and the lack of treatment for many Filipinos. Because without medical monitoring and treatment of CHB the risk of progression to liver failure and death is 25–30%, the ultimate medical and societal costs will be very high if the Philippines fails to properly address hepatitis B infection. It will be very important to move forward with programs that can help to ensure universal vaccination of newborns, screening and vaccination nationwide, and monitoring and treatment for CHB persons. It will also be crucial to address transmission of HBV in the health‐care setting (via contaminated needles and syringes and inadequately sterilized hospital equipment) and via injection drug use and tattooing. Because of the relatively low average per capita income and the lack of coverage by PhilHealth of outpatient visits and medications, there is an urgent need to move forward with a nationally supported program that includes education for both the general public and health‐care workers on liver disease and screening for hepatitis viruses, followed by, as appropriate, vaccination or treatment, with expanded government coverage for these for all those who could not otherwise afford it.
- 28 April 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (5) , 945-952
Open AccessChronic hepatitis B virus in the Philippines
Multiple studies have shown a high prevalence of chronic hepatitis B (CHB) infection in the Philippines, not only in high‐risk populations but also in the general population. The most recent national study estimated HBsAg seroprevalence to be 16.7%, corresponding to an estimated 7.3 million CHB adults. The factors underlying the high prevalence of CHB and its sequelae include the inadequate use of vaccination for prevention and the lack of treatment for many Filipinos. Because without medical monitoring and treatment of CHB the risk of progression to liver failure and death is 25–30%, the ultimate medical and societal costs will be very high if the Philippines fails to properly address hepatitis B infection. It will be very important to move forward with programs that can help to ensure universal vaccination of newborns, screening and vaccination nationwide, and monitoring and treatment for CHB persons. It will also be crucial to address transmission of HBV in the health‐care setting (via contaminated needles and syringes and inadequately sterilized hospital equipment) and via injection drug use and tattooing. Because of the relatively low average per capita income and the lack of coverage by PhilHealth of outpatient visits and medications, there is an urgent need to move forward with a nationally supported program that includes education for both the general public and health‐care workers on liver disease and screening for hepatitis viruses, followed by, as appropriate, vaccination or treatment, with expanded government coverage for these for all those who could not otherwise afford it.
- Open Access
- 30 September 2015
- Published by Philippine College of Physicians
- Vol. 53 (3) , 3-9
Clinical Practice Guidelines on the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD)
In the last two decades gastroesophageal reflux disease (GERD), initially thought to be a disease only common in the West, is described increasingly in Asia, including the Philippines. A recent local report indicated that the prevalence of erosive esophagitis (EE), a common complication of GERD, has more than doubled, i.e., 2.9% to 6.3%, between the two time periods of 1994–1997 and 2000–2003, respectivel y . GERD causes recur rent annoying symptoms which are common reasons for clinic visits and consultations thus, it is the objective of these guidelines to provide both primary care physicians (PCPs) and specialists a current, evidence-based, country-specific recommendations for the optimal management of GERD. These guidelines are intended to empower PCPs to make a clinic-based diagnosis of GERD, to start an empiric acid-suppressive therapy in the appropriate patient, and direct them to select which GERD patient may need to undergo investigations to ascertain further the diagnosis of GERD or to assess outcomes of therapy. We acknowledge that studies published in the future may influence the impact on our confidence on the recommendations enumerated in these guidelines thus, we commit to update this document when it is deemed appropriate. Keywords: Gastroesophageal reflux disease, erosive esophagitis, non-erosive reflux disease, refractory GERD, extraesophageal GERD, Barrett’s esophagus, proton pump inhibitor, upper endoscopy, heartburn, acid regurgitation, alarm features
- 30 September 2015
- Published by Philippine College of Physicians
- Vol. 53 (3) , 3-9
Open AccessClinical Practice Guidelines on the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD)
In the last two decades gastroesophageal reflux disease (GERD), initially thought to be a disease only common in the West, is described increasingly in Asia, including the Philippines. A recent local report indicated that the prevalence of erosive esophagitis (EE), a common complication of GERD, has more than doubled, i.e., 2.9% to 6.3%, between the two time periods of 1994–1997 and 2000–2003, respectivel y . GERD causes recur rent annoying symptoms which are common reasons for clinic visits and consultations thus, it is the objective of these guidelines to provide both primary care physicians (PCPs) and specialists a current, evidence-based, country-specific recommendations for the optimal management of GERD. These guidelines are intended to empower PCPs to make a clinic-based diagnosis of GERD, to start an empiric acid-suppressive therapy in the appropriate patient, and direct them to select which GERD patient may need to undergo investigations to ascertain further the diagnosis of GERD or to assess outcomes of therapy. We acknowledge that studies published in the future may influence the impact on our confidence on the recommendations enumerated in these guidelines thus, we commit to update this document when it is deemed appropriate. Keywords: Gastroesophageal reflux disease, erosive esophagitis, non-erosive reflux disease, refractory GERD, extraesophageal GERD, Barrett’s esophagus, proton pump inhibitor, upper endoscopy, heartburn, acid regurgitation, alarm features
- 20 August 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (s3) , S44-S48
Non‐pharmacologic treatment strategies in gastroesophageal reflux disease
In the West, gastroesophageal reflux disease (GERD) is a common and well-recognized disease. Lately, it has been described as an emerging problem in the East as well. While it is not a rapidly fatal illness, it causes a myriad of disturbing symptoms that remarkably reduce the patients' quality of life (QOL). The economic impact that results from multiple consultations, diagnostic investigations, and administration of a variety of treatment regimens, including surgery, is enormous. The operative management for GERD is fundoplication, for example Toupet (270 degree wrap of the distal esophagus) and Nissen (360 degree wrap of the distal esophagus). These surgical procedures are aimed at permanently controlling acid reflux by reconstructing the gastroesophageal junction. Currently, the ease, aesthetic advantages, and the comparable outcomes achieved by minimally invasive laparoscopic fundoplication have rekindled interest in the operative alternatives of GERD management. Fundoplication controls or diminishes considerably the severity of the symptoms associated with GERD. However, appearance of new symptoms i.e. dysphagia, 'gas-bloat syndrome', etc. as postoperative events have been reported. Recently, several innovative endoluminal treatment modalities have been introduced, namely; endoscopic plicator/suturing devices, bulking injections, and radiofrequency treatment. They are focused on enhancing the performance of a malfunctioning lower esophageal sphincter. While results of several case series reflect substantial improvements in GERD-HRQL scores, lack of long-term durability data is a major concern when recommending these novel, relatively simple, peroral techniques to a long suffering patient. It is clear that these therapies are still evolving and long-term outcomes of properly designed comparative efficacy trials are awaited.
- 20 August 2004
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 19 (s3) , S44-S48
Non‐pharmacologic treatment strategies in gastroesophageal reflux disease
In the West, gastroesophageal reflux disease (GERD) is a common and well-recognized disease. Lately, it has been described as an emerging problem in the East as well. While it is not a rapidly fatal illness, it causes a myriad of disturbing symptoms that remarkably reduce the patients' quality of life (QOL). The economic impact that results from multiple consultations, diagnostic investigations, and administration of a variety of treatment regimens, including surgery, is enormous. The operative management for GERD is fundoplication, for example Toupet (270 degree wrap of the distal esophagus) and Nissen (360 degree wrap of the distal esophagus). These surgical procedures are aimed at permanently controlling acid reflux by reconstructing the gastroesophageal junction. Currently, the ease, aesthetic advantages, and the comparable outcomes achieved by minimally invasive laparoscopic fundoplication have rekindled interest in the operative alternatives of GERD management. Fundoplication controls or diminishes considerably the severity of the symptoms associated with GERD. However, appearance of new symptoms i.e. dysphagia, 'gas-bloat syndrome', etc. as postoperative events have been reported. Recently, several innovative endoluminal treatment modalities have been introduced, namely; endoscopic plicator/suturing devices, bulking injections, and radiofrequency treatment. They are focused on enhancing the performance of a malfunctioning lower esophageal sphincter. While results of several case series reflect substantial improvements in GERD-HRQL scores, lack of long-term durability data is a major concern when recommending these novel, relatively simple, peroral techniques to a long suffering patient. It is clear that these therapies are still evolving and long-term outcomes of properly designed comparative efficacy trials are awaited.